Treatment With the Nitric Oxide Synthase Inhibitor L-Name Provides a Survival Advantage in a Mouse Model of Kras Mutation-Positive, Non-Small Cell Lung Cancer

Oncotarget - United States
doi 10.18632/oncotarget.9874
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

KRAS Mutation, KRAS–LCS6 Polymorphism, and Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2010English

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi
2020English

Response to Treatment and Survival of Patients With Non-Small Cell Lung Cancer Undergoing Somatic EGFR Mutation Testing

Oncologist
Cancer ResearchMedicineOncology
2007English

Correlation Between KRAS Mutation Status and Response to Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer☆

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2016English

Circulating Tumor DNA Provides a Sneak Peek Into Treatment Responses in Non–Small Cell Lung Cancer

Cancer Research
Cancer ResearchOncology
2019English

A Novel PI3K Inhibitor iMDK Suppresses Non-Small Cell Lung Cancer Cooperatively With a MEK Inhibitor

Experimental Cell Research
Cell Biology
2015English

Prognostic Value of KRAS/TP53/PIK3CA in Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2019English

Social Factors, Treatment, and Survival in Early-Stage Non-Small Cell Lung Cancer.

American Journal of Public Health
EnvironmentalPublic HealthOccupational Health
1998English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy